CAYA Cancer Retrospective Cohort Study

Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies. Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare. This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.

NCT Number	NCT07246213
Lead Sponsor	Resonance, Inc. Collaborators: Servier Affaires Médicales
Conditions	Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer, Childhood Cancers, Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma (LBL)
Enrollment	18,000 participants
Start Date	2025-06-04
Primary Completion	2028-06-04 (estimated)
Study Completion	2028-12-04 (estimated)
Updated on ClinicalTrials.gov	2025-12-19